causative genes for human genetic disease are now being discovered at a remarkable rate. in some cases these genes have well-known functions, but in many other cases they have not been the subject of much previous study and little or nothing is known about their function. as recognized in international rare diseases research consortium’s (irdirc) policies and guidelines, model organisms such as yeast, c. elegans, drosophila, zebrafish, and mice, provide powerful and efficient tools to validate putative disease genes and to gain understanding about the functions of unknown genes. canada has a great deal of fundamental research strength in these areas, and we have seen over the past few years the potential of collaboration between these research communities and clinical geneticists who are working directly with people who are living with rare genetic diseases.

this program builds on the success of the research catalyst network: rare diseases program, launched in 2014, which led to the development of the rare diseases models and mechanisms network (rdmm). thanks in part to this network, the first of its kind around the globe, canada’s national gene discovery programs are progressing at a higher success rate than anticipated, largely because of the international uptake of the matchmaker exchange initiative, which has accelerated the identification of additional families with the same rare disease. the current volume of novel genes waiting for a connection to a model organism expert continue to grow, thereby supporting the second launch of this program. moreover, the rdmm inspired and supported the development of similar initiatives in other countries, and for about 10% of submitted genes, no suitable model could be identified in canada. this second edition of the program therefore seeks to support a rare disease network aiming at maintaining canada’s leadership in enabling clinical geneticists who are identifying rare disease gene mutations to collaborate with model organism researchers with expertise in the cognate gene’s function, and to develop the capacity to study genes for which no suitable models can be identified in canada or in other countries with similar networks.  this will provide a powerful incentive for expanded international collaborations between canadian model organism researchers and clinical geneticists elsewhere, and will enable reciprocal arrangements whereby model organism researchers elsewhere will be funded by other networks to collaborate with canadian clinicians.

a strong rare disease research network will include the following:

• significant national representation from the clinical genetics research community who are identifying rare disease genes, including linkages with the international community of rare disease researchers
• significant national representation of researchers working with well-established organisms for modeling human disease
• a database infrastructure and informatics tools supporting data sharing with similar international databases
• adherence to irdirc’s policies and procedures.

such a network will also:

• be inclusive, and have a process in place to recruit and integrate new members throughout the term of the grant
• develop a robust process for initiating catalytic functional characterization research projects

to ensure that all interested individuals signal their interest and have the opportunity to participate in the network you can use the icpermed partnering tool, which facilitates networking in personalized medicine research.

the funded network will be invited to participate in the activities of irdirc.

funds available

cihr and partner(s) financial contributions for this initiative are subject to availability of funds. should cihr or partner(s) funding levels not be available or are decreased due to unforeseen circumstances, cihr and partner(s) reserve the right to reduce, defer or suspend financial contributions to grants received as a result of this funding opportunity.

• the total amount available from cihr for this funding opportunity is $1,120,000, in addition, up to $560,000 is being provided by genome canada, enough to fund one (1) national network. this amount may increase if additional funding partners participate.
• the maximum amount to fund one (1) national network is $420,000 per year for up to 4 years.

the antimicrobial resistance: point of care diagnostics in human health phase 2 funding opportunity is expected to:

• improve rational use of antibiotics and clinical management by increasing availability, timeliness, and uptake of clinically relevant point-of-care diagnostic tools in amr.
• integrate evidence-informed therapeutic approaches and prevention interventions into health care practice and policy.
• determine commercial viability and show direct clinical applicability of a technology or tool that has passed the preliminary design developmental phase.
• enhance capacity to conduct international, intersectoral and interdisciplinary amr research through collaboration and training of researchers and health care professionals.

fy18 bcrp program announcements and general application instructions for the following award mechanisms are posted on grants.gov. 

as directed by the office of the assistant secretary of defense for health affairs, the defense health agency (dha), j9 research and development directorate manages the defense health program (dhp) research, development, test, and evaluation (rdt&e) appropriation.  the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp).

applications submitted to the fy18 bcrp must address one or more of the following overarching challenges:

·         prevent breast cancer (primary prevention)

·         identify determinants of breast cancer initiation, risk, or susceptibility

·         distinguish deadly from non-deadly breast cancers

·         conquer the problems of over diagnosis and overtreatment

·         identify what drives breast cancer growth; determine how to stop it

·         identify why some breast cancers become metastatic

·         determine why/how breast cancer cells lie dormant for years and then re-emerge; determine how to prevent lethal recurrence

·         revolutionize treatment regimens by replacing them with ones that are more effective, less toxic, and impact survival

·         eliminate the mortality associated with metastatic breast cancer

http://cdmrp.army.mil/funding/bcrp

breakthrough award level 1 & 2– letter of intent due may 16, 2018 for level 1 & 2

·         investigators at all academic levels (or equivalent)

·         senior postdoctoral fellows who do not meet the eligibility requirements of the breakthrough fellowship award are encouraged to apply under funding levels 1 and 2

·         each investigator may submit only one funding level 1 application and one funding level 2 application as a pi or initiating pi.

·         supports promising research that has the potential to lead to or make breakthroughs in breast cancer.

·         potential impact of the research may be near-term or long-term, but it must be significant and go beyond an incremental advancement.

·         partnering pi option allows two pis, termed initiating and partnering pis, to collaborate on a single application.

·         it is the responsibility of the pi to select the funding level that is most appropriate for the research proposed.  the funding level should be selected based on the scope of the research project, rather than the amount of the budget.

·         there are no limitations on the number of applications for which an investigator may be named as a

·         partnering pi.  however, applicants are discouraged from submitting as a partnering pi on multiple applications unless they are clearly unique, meaningful collaborations addressing distinct research questions.

·         additional funds are available for applications submitted under the partnering pi option.

·         clinical trials are not allowed.

·         submission of a letter of intent is required prior to full application submission.

·         funding level 1:

·         maximum funding of $375,000 for direct costs (plus indirect costs)

·         maximum period of performance is 3 years

·         funding level 1 – partnering pi option:

·         maximum funding of $600,000 for direct costs (plus indirect costs)

·         maximum period of performance is 3 years

·         funding level 2:

·         maximum funding of $750,000 for direct costs (plus indirect costs)

·         maximum period of performance is 3 years

·         funding level 2 – partnering pi option:

·         maximum funding of $1m for direct costs (plus indirect costs)

·         maximum period of performance is 3 years

breakthrough award level 3 & 4– preproposal may 15, 2018

·         independent investigators at all academic levels (or equivalent) are eligible.

·         each investigator may submit one funding level 3 pre-application and on funding level 4 pre-application as a pi or initiating pi.

·         supports promising research that has the potential to lead to or make breakthroughs in breast cancer.

·         potential impact of the research may be near-terms or long-term, but it must be significant and go beyond an incremental advancement.

·         partnering pi option allows two pis, termed initiating and partnering pis, to collaborate on a single application.

·         it is the responsibility of the pi to select the funding level that is most appropriate for the research proposed.  the funding level should be selected based on the scope of the research project, rather than the amount of the budget.

·         clinical trials are allowed.

·         there are no limitations on the number of applications for which an investigator may be named as a partnering pi.  however, applicants are discouraged from submitting as a partnering pi on multiple applications unless they are clearly unique, meaningful collaborations addressing distinct research questions.

·         pis must include two or more breast cancer advocates on their research team.

·         submission of a preproposal is required; application submission is by invitation only.

funding level 3:

maximum funding of $2.5m in direct costs (plus indirect costs)

maximum period of performance is 4 years

funding level 3 – partnering pi option:

maximum funding of $4m for direct costs (plus indirect costs)

maximum period of performance is 4 years

funding level 4 and funding level 4 – partnering pi option:

maximum funding of $10m for direct costs (plus indirect costs)

maximum period of performance is 4 years

breakthrough fellowship award – letter of intent due may 16, 2018

as of the application submission deadline, all eligible pis must have:

·         successfully completed the requirements for a doctoral or medical degree, and

·         been in the laboratory or clinical research setting in which the proposed research is to be performed for no more than 2 years, and

·         a total of less than 4 years’ experience in a postdoctoral fellowship or mentored clinical research training program (excludes any clinical residency or fellowship training)

mentor

must have breast cancer research experience, including current funding and recent publications

·         supports exceptionally talented, “best and brightest” recent doctoral or medical graduates in pursuit of promising research that has the potential to lead to or make breakthroughs in breast cancer.

·         potential impact of the research may be near-term or long-term, but it must be significant and go beyond an incremental advancement.

·         individualized researcher development plan and mentorship should prepare the pi for an independent career at the forefront of breast cancer research or patient care.

·         the pi is not required to have previous experience in breast cancer research.

·         maximum funding of $300,000 for direct costs (plus indirect costs)

·         maximum period of performance is 3 years

era of hope scholar award – letter of intent due may 16, 2018

independent, non-mentored investigators within 6 years of their last training position (e.g., postdoctoral fellowship, medical residency, clinical fellowship) as of the application submission deadline

·         submission of a letter of intent is required prior to full application submission.

·         supports exceptionally talented, creative early-career scientists who have demonstrated that they are the “best and brightest” in their fields.

·         pis should articulate a vision that challenges current dogma and demonstrates an ability to look beyond tradition and convention.

·         pis must exhibit strong potential for leadership in breast cancer.

·         experience in breast cancer research is not required; however, the application must focus on breast cancer, and the pi must maintain a 50% dedication of his/her full-time professional effort during the award period to breast cancer research.

·         pis are required to include breast cancer advocates on their research team.

·         preliminary data are allowed, but not required.

·         maximum funding of $2.5m for direct costs (plus indirect costs)

·         maximum period of performance is 4 years

innovator award – preproposal due may 15, 2018

associate professor or above (or equivalent).

·         supports visionary individuals who have demonstrated creativity, innovative work, and leadership in any field.

·         provides opportunity to pursue novel, visionary, high-risk ideas that will accelerate progress toward ending breast cancer.

·         pis must include two or more breast cancer advocates on their research team.

·         preproposal is required; application submission is by invitation only.

·         maximum funding of $5m for direct costs (plus indirect costs).

·         maximum period of performance is 4 years

distinguished investigator award – preproposal due may 15, 2018

assistant professor or above (or equivalent) and more than 6 years beyond the pi’s last training position as of the application submission deadline

·         supports established visionary leaders from any field to pursue innovative ideas that could accelerate progress toward ending breast cancer.

·         the pi must propose research that is a fundamental shift from his/her track record of research.

·         does not support continuation of or minor advancement from the pi’s published line of research.

·         if the pi is not an established breast cancer researcher, he/she must clearly articulate a motivation and commitment for proposing a conceptual shift in his/her research and must include at least one collaborator with breast cancer expertise.

·         pis must include two or more breast cancer advocates on their research team.

·         high-risk/high-reward projects pursuing innovative new paradigms are encouraged, but not required.

·         preproposal is required; application submission is by invitation only.

·         maximum funding of $3m for direct costs (plus indirect costs)

·         maximumperiod of performance is 4 years

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final program announcements and general application instructions available for electronic downloading from the grants.gov website.  the application package containing the required forms for each award mechanism is also found on grants.gov.  a listing of all cdmrp funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

applications must be submitted through the federal government’s single-entry portal, grants.gov.  for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the bcrp or other cdmrp-administered programs, please visit the cdmrp website (http://cdmrp.army.mil).

partnership engage grants are expected to respond to the objectives of the insight program and the connection program. they provide short-term and timely support for partnered research activities that will inform decision-making at a single partner organization from the public, private or not-for-profit sector. the small-scale, stakeholder-driven partnerships supported through the partnership engage grants are meant to respond to immediate needs and time constraints facing organizations in non-academic sectors. in addressing an organization-specific need, challenge and/or opportunity, these partnerships let non-academic organizations and postsecondary researchers access each other’s unique knowledge, expertise and capabilities on topics of mutual interest.

this call for preliminary proposals “partnerships for her voice, her choice” is part of the $650-million funding over 3 years announced by minister bibeau in support of sexual and reproductive health and rights (srhr) as a means of advancing gender equality and empowerment of all women and girls in line with the feminist international assistance policy. the call focuses on comprehensive sexual education; reproductive health services and investments in family planning and contraceptives; the prevention of and response to sexual and gender-based violence, including child, early and forced marriage, and female genital mutilation and cutting; and initiatives that support the right to choose safe and legal abortion, as well as access to post-abortion care, including in fragile and conflict-affected settings.

you must submit your preliminary proposal through the partners@international portal before the deadline. we will not accept any late submissions. please read the portal instructions carefully and plan to submit your application at least 3 days before the closing date to ensure that technical difficulties do not prevent you from submitting your proposal by 12:00 p.m. (noon) eastern daylight time on may 1, 2018.

the total amount of funding available under the partnerships for her voice, her choice (sexual and reproductive health and rights) call for preliminary proposals is $40 million from fiscal years 2018/19 to 2023/24. we may fund any number of proposals, or none, up to the maximum funding available.

the submission of a preliminary proposal is the first stage of a two-stage application process. funding cannot be provided on the basis of a preliminary proposal. be sure to review the instructions in how to apply for funding through a call for preliminary proposals before beginning your application.

since organizations can only submit one application under this call, applicants must notify the office of research services (ahacquo1@lakeheadu.ca) of their intention to apply to this program no later than april 3, 2018.

the science for peace and security (sps) programme promotes dialogue and practical cooperation between nato member states and partner nations based on scientific research, technological innovation and knowledge exchange. the sps programme offers funding, expert advice and support to tailor-made, security-relevant activities that respond to nato’s strategic objectives.

the sps programme supports collaboration through three established grant mechanisms: multi-year research projects, research workshops, and training courses.

conference and workshop grants are for amounts up to $20,000. in accordance with the mission of the foundation, priority is given to events that foster the creation of an international community of research scholars in anthropology and advance significant and innovative anthropological research.

conferences are defined as public events that are comprised primarily of oral and poster presentations to a larger audience of anthropologists. priority is given to major conferences sponsored by large international anthropological organizations (e.g., the european association of social anthropologists, european anthropological association, pan african anthropological association, and latin american anthropological association) that serve as their annual or periodic meetings. the majority of the funds granted to such conferences is expected to be used towards expenses for international scholars who are making presentations at the conference and would not otherwise be able to attend.

workshops are defined as working meetings that focus on developing and debating topical issues in theoretical anthropology. workshops involve a small group of scholars who meet for a sufficient period of time to deal intensively with the topic. priority is given to those workshops that devote the majority of time to discussion and debate rather than to the presentation of papers. it is expected that workshops will result in a publication.

dissertation fieldwork grants are awarded to aid doctoral or thesis research. the program contributes to the foundation's overall mission to support basic research in anthropology and to ensure that the discipline continues to be a source of vibrant and significant work that furthers our understanding of humanity's cultural and biological origins, development, and variation. the foundation supports research that demonstrates a clear link to anthropological theory and debates, and promises to make a solid contribution to advancing these ideas. there is no preference for any methodology, research location, or subfield. the foundation particularly welcomes proposals that employ a comparative perspective, can generate innovative approaches or ideas, and/or integrate two or more subfields

the law foundation of ontario understands the importance of providing stable core funding to nonprofit organizations working to provide essential services and fill important gaps in the justice sector.

the foundation’s new catalyst program will provide any nonprofit organization working to advance access to justice with an opportunity to apply for up to $150,000 per year of core funding for three years.

the foundation will make a call for applications only once per three-year cycle. each successful grantee will receive a one-year grant, which is renewable for another two years. the board of trustees will review the status of the work annually and, providing things are proceeding appropriately, will renew the grant for a second (and then a third) year.